The Federal Trade Commission is accusing several drugmakers of violating antitrust laws with agreements that delayed availability of cheaper generic versions of two pain treatments.
The FTC alleges Endo Pharmaceuticals Inc., maker of Opana ER pain pills and the Lidoderm pain patch, paid Impax Laboratories and Watson Laboratories, respectively, to delay selling their approved generic versions of the products.
